GC Aesthetics said Friday that it has raised $40 million in financing. The investors were OrbiMed, Montreux Equity Partners and Oyster Capital. According to the company, the capital infusion will be used for international expansion, product development and launches. Based in Dublin, GC Aesthetics is a maker of breast implants.
DUBLIN, February 21, 2014 /PRNewswire/ —
GC Aesthetics (http://www.gcaesthetics.com), one of the largest independent aesthetic companies globally, has raised $40M of financing from new investor OrbiMed, alongside nearly $20M from existing investors including Montreux Equity Partners and Oyster Capital. This financing will fuel further international expansion, new product development and launches. It will continue to support GC Aesthetics’ vision to become the world’s leading independent medical aesthetics company.
GC Aesthetics is a global leader in the aesthetic and plastic surgery market with their flagship brands: UK-based Nagor and France-based Eurosilicone. GC Aesthetics has had manufacturing plants in Europe for over 30 years, and plans further expansion of its operations in Europe to meet the growing demand. The company, whose products sell in over 90 countries, has been growing their business worldwide with a new executive team at the helm since the beginning of 2013.
Ayse Kocak, CEO of GC Aesthetics and the industry’s first-ever female CEO says: “We are delighted to have secured this funding that will allow GC Aesthetics consolidate its position as a market leader in aesthetics, and one which continues to keep women’s interests at the forefront of all our goals. This has been an exciting year for us and we have laid the foundations to launch groundbreaking initiatives. This funding will enable us to maximise further growth, introduce our quality products to new markets and give patients and surgeons more choice than ever before”.
Daniel K. Turner III, Managing Director of Montreux Equity Partners and Chairman of GC Aesthetics, added, “Ayse and the GC Aesthetics management team are transforming the aesthetics market with their focus on the health and wellness of women. Our continued financial commitment demonstrates our excitement for GC Aesthetics growth prospects as it becomes a global market leader in aesthetics.”
About GC Aesthetics
GC Aesthetics, which stands for Global Consolidated Aesthetics, was founded in 2007 and is the umbrella company for two leading implant manufacturers: Nagor and Eurosilicone. The Dublin-based privately owned company has more than 60 years of combined experience and excellence in implant development, manufacture and innovation and currently manufactures and sells breast implants in 90 countries, offering a wide product range with nearly 600 types of implant. The company manufactures its products at its own facilities based in Scotland, England and France and produces to the highest European standards. GC Aesthetics is committed to the continuous improvement and evolution of the Eurosilicone and Nagor product lines and to educating consumers by providing clear information on implants.
To contact GC Aesthetics, please email [email protected] and to visit the GC Aesthetics website please go to http://www.gcaesthetics.com
OrbiMed (http://www.orbimed.com) is a leading investment firm dedicated exclusively to the healthcare sector, with over $9 billion in assets under management. OrbiMed invests globally across the spectrum of healthcare companies, from venture capital start-ups to large multinational companies. OrbiMed’s team of more than 80 employees manages a series of private equity funds, public equity funds, royalty/debt funds and other investment vehicles. OrbiMed maintains its headquarters in New York City, with additional offices in San Francisco, Shanghai, Mumbai and Herzliya.
About Montreux Equity Partners
Montreux is dedicated to making growth capital investments in category leading companies with products, technologies, and services that are advancing health. Since 1993, Montreux has invested in more than 50 companies, including MAKO Surgical (acquired by Stryker), SkinMedica (acquired by Allergan), Renal CarePartners (acquired by Ambulatory Services of America), Great Lakes Health Plan (acquired by United Healthcare), and Orexigen (Nasdaq: OREX). Montreux is based in San Francisco, CA and is currently investing out of its fifth fund. For more information, visit mepvc.com.
About Oyster Capital
Oyster was founded in 2000 by Bill McCabe, one of Ireland’s most successful entrepreneurs, and the firm invests in technology, software, waste and energy businesses. Since its inception, it has invested in more than 30 companies and has offices both in Ireland and USA.